Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial-Reference-Cited by-同舟云学术

Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial

Published:2021-09 Issue:9 Volume:22 Page:1240-1249
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Nordström Tobias,Discacciati Andrea,Bergman Martin,Clements Mark,Aly Markus,Annerstedt Magnus,Glaessgen Axel,Carlsson Stefan,Jäderling Fredrik,Eklund Martin,Grönberg Henrik,Cavalli-Björkman Carin,Björklund Astrid,Hune Britt-Marie,Clements Mark,Hao Shuang,Discacciati Andrea,Grönberg Henrik,Eklund Martin,Nordström Tobias,Carlsson Stefan,Aly Markus,Walldén Mats,Steinberg Ola,Andersson Karl,Jäderling Fredrik,Wimmercranz Fredrik,Meurling Edward,Gleassgen Axel,Majeed Nada,Awadelkarim Rihab,Fyhr Ing-Marie,Sandström Dag,Waage Linda,Imamov Otabek,Lantz Rafael,Thorstensson Andreas,Stiernstedt Carl,Wande Dushaid,Trygg Gunnar,Söderbäck Harald,Michajlowski Jerzy,Leykamm Lars,Svedberg Nils-Erik,Bergman Tommy,Sabockis Raimundas,Akrawi Sirvan,Bergman Martin,Annerstedt Magnus

Funder

Percy Falks Stiftelse For Forskning Betraffande Prostata- Och Brostcancer

Cancerfonden

Vetenskapsradet

FORTE

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Prostate-cancer mortality at 11 years of follow-up;Schröder;N Engl J Med,2012

2. NCCN guidelines updates: prostate cancer and prostate cancer early detection;Carroll;J Natl Compr Canc Netw,2018